MedTrace Logo

The Effect of Lactobacillus Delbrueckii Subsp. Bulgaricus on Human's Weight Reduction

NCT06244186 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2024-02-06

No results posted yet for this study

Summary

To evaluate the improvement in weight, body fat, and BMI after adding probiotics as a once-daily therapy for 84 days in overweight individuals.

Conditions

  • Overweight and Obesity

Interventions

DIETARY_SUPPLEMENT

Probiotics

Probiotics contains a probiotic known as Lactobacillus delbrueckii subsp. Bulgaricus, a key bacterium utilized in the production of yogurt, cheeses, and various naturally fermented products. Studies suggest that the metabolites of Lactobacillus bulgaricus can enhance immunity and digestion, reduce the risk of infection, and lower blood cholesterol levels. The composition of probiotics has been developed by TCI CO., Ltd.

DIETARY_SUPPLEMENT

Placebo

Placebo is provided by TCI CO., Ltd.

Sponsors & Collaborators

  • TCI Co., Ltd.

    collaborator INDUSTRY

  • China Medical University Hospital

    lead OTHER

Principal Investigators

  • Kuo-Chin Huang, PhD · China Medical University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-10
Primary Completion
2022-11-01
Completion
2023-11-03

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06244186 on ClinicalTrials.gov